Abstract
Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8 + T-cell immunity.
Keywords: COVID-19; SARS-CoV-2; antibodies; antibody-dependent enhancement; neutralization; spike protein; vaccine.
All Keywords
【저자키워드】 COVID-19, antibodies, SARS-CoV-2, Vaccine, Antibody-dependent enhancement, neutralization, Spike protein, 【초록키워드】 Vaccine, Vaccines, Neutralizing antibodies, antibody, Antibody-dependent enhancement, neutralization, variant, risk, CD8, Spike protein, nucleocapsid protein, memory, SARS-CoV-2 evolution, T-cell immunity, B-cell, Spike proteins, ORF1ab, infection rates, novel vaccines, ORF1, spike protein of SARS-CoV-2, approach, current, reduced, the spike protein, induce, antibody response against, 【제목키워드】 mRNA vaccination,
【저자키워드】 COVID-19, antibodies, SARS-CoV-2, Vaccine, Antibody-dependent enhancement, neutralization, Spike protein, 【초록키워드】 Vaccine, Vaccines, Neutralizing antibodies, antibody, Antibody-dependent enhancement, neutralization, variant, risk, CD8, Spike protein, nucleocapsid protein, memory, SARS-CoV-2 evolution, T-cell immunity, B-cell, Spike proteins, ORF1ab, infection rates, novel vaccines, ORF1, spike protein of SARS-CoV-2, approach, current, reduced, the spike protein, induce, antibody response against, 【제목키워드】 mRNA vaccination,
{{{ 추상적인 }}}
SARS-CoV-2의 스파이크 단백질에 대한 B 세포 매개 항체 반응을 유도하는 현재의 백신은 감염률을 현저히 감소시켰습니다. 그러나 SARS-CoV-2 진화의 결과로 새로운 변이체의 출현은 ORF1ab 또는 뉴클레오캡시드 단백질과 함께 돌연변이 특이적 스파이크 단백질을 표적으로 하는 T 세포 기반의 새로운 백신의 개발을 필요로 합니다. 이 접근법은 기억 CD8 + T 세포 면역뿐만 아니라 항체 의존성 강화의 위험 없이 고도로 중화되는 항체를 유도하는 데 더 적합합니다.
{{ 키워드: }} 코로나19; 사스 코로나바이러스 2; 항체; 항체 의존성 강화; 중립화; 스파이크 단백질; 백신.